Veritas In Silico ＜130A＞ announced on the 9th that it will form a partnership with Liverpool ChiroChem (LCC) in the joint drug discovery business of small-molecule pharmaceuticals targeting RNA.
In this partnership, by combining LCC's chemical drug platform with its own drug discovery platform ibVIS(R), they aim to create assets (fragment compounds) targeting undisclosed mRNA targets. The company has already conducted screening analysis on fragment compounds owned by LCC since July. Both companies have agreed to proceed with the drug discovery and development of small-molecule pharmaceuticals targeting RNA based on the positive results.
Both companies will continue to proceed with the necessary procedures for implementing this partnership, such as contract signing, in the future.
